Loading...
Loading...
DRMA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 1,812.0K |
| Operating I/L | -1,812.0K |
| Other Income/Expense | 92.8K |
| Interest Income | 92.8K |
| Pretax | -1,719.2K |
| Income Tax Expense | -1.8K |
| Net Income/Loss | -1,719.2K |
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company specializing in pharmaceutical product candidates for medical and aesthetic skin conditions. Their lead product candidate, DMT310, has completed Phase IIb clinical trial for acne treatment and is in Phase 2 clinical trial for rosacea. Additionally, the company is developing DMT410 for hyperhidrosis and aesthetic conditions. Dermata Therapeutics generates revenue through the identification, development, and commercialization of these pharmaceutical product candidates for the treatment of skin conditions.
